A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing
CHRA
CHRA
Sponsor study identifier
observational
156
4 countries
5
Study Start
August 2010
Actual (reported)Primary Completion
September 2023
Actual (reported)Study Completion
September 2023
Actual (reported)This study is designed as a multi-center, nonrandomized, uncontrolled, unblinded, prospective clinical outcomes investigation to evaluate the short, mid and long term performance of the PyroTITAN™ HRA Shoulder prosthesis humeral replacement.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2010
Actual (reported)November 4, 2014
Actual (reported)April 1, 2015
Actual (reported)September 2023
Actual (reported)September 2023
Actual (reported)December 24, 2025
Actual (reported)Device Survival
Clinical success was determined by the percentage of shoulders with device survival. Survival of the device was measured by the Kaplan-Meier survival estimate with survival defined as all the following: * Device remained implanted * Absence of device-related complications requiring surgical replacement, removal, or augmentation of components * Freedom from chronic dislocation
up to 117 months
Radiographic Success
2 years, 3 years, 4 years, 5 years, 8 years and 10 years
ASES Score
Baseline, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 8 years, and 10 years
Visual Analog Scale (VAS) Pain Score
Baseline, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 8 years, and 10 years
Visual Analog Scale (VAS) Satisfaction Score
3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 8 years, and 10 years
The Western Ontario of the Shoulder Index (WOOS) Score
Baseline, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 8 years, and 10 years
Primary cohort will receive the PyroTITAN HRA device
Humeral resurfacing using the PyroTITAN HRA device
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Subjects who require humeral head resurfacing arthroplasty.
Brisbane Hand & Upper Limb Clinic
Brisbane, Queensland, 4001, Australia
Barwon Health
Geelong, Victoria, 3220, Australia
Institut Nices
Nice, 06000, France
Danderyd Hospital
Stockholm, S-182 88, Sweden
Wrightington Hospital
Wigan, Wrightington, WN6 9EP, United Kingdom
The study was managed by Ascension Orthopedics, Inc prior to Smith+Nephew Inc. (Memphis) becoming the sponsor in January 2021. This study was not designed nor controlled/monitored by Smith+Nephew Inc. (Memphis), except for the final follow-up phase. The data reported is based on the data available since the time of Smith+Nephew's acquisition of Ascension Orthopedics, Inc.
Julie Lankiewicz
Smith & Nephew, Inc.
156 participants (actual enrollment reported by the registry).
First Submitted
November 4, 2014
First Posted
April 1, 2015
Study Start
August 2010
Actual (reported)General vs. Intrathecal Anesthesia for Total Knee Arthroplasty
Contact the study team to confirm eligibility.
Primary Completion
September 2023
Actual (reported)Study Completion
September 2023
Actual (reported)Last Updated
December 24, 2025
Results First Posted
December 24, 2025
Record last verified: 2024-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: